Literature DB >> 23448483

Structural, biochemical and non-traditional cardiovascular risk markers in PCOS.

Charikleia Christakou1, Evanthia Diamanti-Kandarakis.   

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448483     DOI: 10.2174/1381612811319320011

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

1.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

Review 2.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

Review 3.  Polycystic ovary syndrome: clinical implication in perimenopause.

Authors:  Monika Lenart-Lipińska; Beata Matyjaszek-Matuszek; Ewa Woźniakowska; Janusz Solski; Jerzy S Tarach; Tomasz Paszkowski
Journal:  Prz Menopauzalny       Date:  2014-12-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.